희귀 내분비질환 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the global Rare Endocrine Disease Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Rare Endocrine Disease Treatment Market Size (2024E): US$ 8,500 Mn
• Projected Market Value (2031F): US$ 12,000 Mn
• Global Market Growth Rate (CAGR 2024 to 2031): Moderate

Rare Endocrine Disease Treatment Market - Report Scope:

The global rare endocrine disease treatment market focuses on therapies targeting rare endocrine diseases that lead to obesity and other associated complications. These treatments include addressing a variety of endocrine dysfunctions, such as hypothalamic disorders, polycystic ovarian syndrome, Cushing's syndrome, and hypothyroidism. With advances in research and technology, the treatment landscape has expanded to provide precision-targeted therapies that aim to manage obesity by focusing on hormone regulation and adipogenesis suppression. This market is witnessing collaborations to foster innovation and strengthen diagnostic and therapeutic capabilities.

Market Growth Drivers:

Several factors are fueling the growth of the rare endocrine disease treatment market. Increasing research collaborations and the development of virtual laboratories have expanded access to critical datasets, enabling more effective diagnosis and treatment options. Additionally, the growing prevalence of rare endocrine diseases, combined with rising obesity rates worldwide, has heightened the demand for innovative therapeutic options. Furthermore, technological advancements and improved screening techniques are contributing to the development of targeted therapies. Collaboration platforms like Endocrine Genomics Virtual Laboratory (endoVL) have proven integral by providing secure data sharing and supporting clinical trials. These platforms ensure access to large patient cohorts, allowing researchers to gain robust statistical insights into rare disease treatments.

Market Restraints:

While the market demonstrates promising growth potential, there are certain challenges impeding its progress. One of the most significant hurdles is the rarity of these endocrine disorders, which limits the availability of sufficient patient data to conduct large-scale clinical trials. Moreover, the complexity of gathering qualitative and quantitative data from geographically dispersed populations poses logistical difficulties. High costs associated with research and treatment development, as well as regulatory challenges, are other key barriers. The dependence on clinical trials and cross-border collaborations further adds uncertainty, especially in regions with limited access to specialized healthcare infrastructure.

Market Opportunities:

The rare endocrine disease treatment market is poised to unlock substantial opportunities through strategic technological innovations and research investments. Advanced genomics tools, data-sharing platforms, and AI-powered analysis are expanding the ability to target rare endocrine conditions more effectively. Collaborative research initiatives like endoVL are creating opportunities to conduct large-scale studies, improving the likelihood of novel treatment discovery. Additionally, precision medicine's role in customizing treatment plans for patients with rare endocrine diseases is opening new market avenues. The adoption of novel drug delivery methods and targeted therapies further presents market participants with opportunities to innovate and diversify product portfolios, catering to the growing patient population.

Key Questions Answered in the Report:

• What are the primary factors driving the global growth of the rare endocrine disease treatment market?
• Which therapeutic areas are witnessing the highest adoption trends across various regions?
• How are technological collaborations shaping the competitive landscape of rare endocrine disease treatments?
• Who are the key players driving innovation and competitive strategies within the rare endocrine disease treatment market?
• What are the emerging trends and future projections for market growth from 2017 to 2026?

Competitive Intelligence and Business Strategy:

Leading stakeholders in the global rare endocrine disease treatment market are prioritizing collaborations and technological research to solidify their positions. Companies are actively investing in virtual platforms like endoVL to connect global research groups and harness real-time data for efficient clinical trial execution. With over 8,500 adrenal tumor cases already being tracked via endoVL and more than 25 large-scale clinical trials in progress, the data-sharing initiative has proven crucial for treatment discovery. Market players are utilizing these opportunities to create novel therapies, integrating AI and advanced genomics into the research pipeline. Furthermore, public-private partnerships are helping these players mitigate challenges associated with rare disease research while boosting innovation and product development.

Key Companies Profiled:

• Novartis
• Ipsen
• Pfizer, Inc.
• Teva
• EMD serono
• Novo Nordisk
• Eli Lilly
• Shire
• Amgen, Inc.
• Corcept Therapeutics
• Novelion Therapeutics
• Others.

Rare Endocrine Disease Treatment Market Segmentation:

By Indication:

• Acromegaly
• Central Diabetes Insipidus
• Ahumada-Del Castillo Syndrome
• Hypoparathyroidism
• Other Indications

By Drug Type:

• Biologics
• Organic Compounds

By Mode of Administration:

• Injectables
• Oral
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Table of Contents

1. Global Economic Outlook

2. Global Rare Endocrine Disease Treatment Market - Executive Summary

3. Global Rare Endocrine Disease Treatment Market Overview

• 3.1. Introduction
  • 3.1.1. Global Rare Endocrine Disease Treatment Market Taxonomy
  • 3.1.2. Global Rare Endocrine Disease Treatment Market Definition
• 3.2. Global Rare Endocrine Disease Treatment Market Size (US$ Mn) and Forecast, 2024 - 2031
  • 3.2.1. Global Rare Endocrine Disease Treatment Market Y-o-Y Growth
• 3.3. Global Rare Endocrine Disease Treatment Market Dynamics
• 3.4. Supply Chain
• 3.5. Cost Structure
• 3.6. USA, EU & Japan Orphan Designations per Year & Cumulative
• 3.7. Worldwide Top 20 Orphan Drug Manufacturers
• 3.8. Wheel of Fortune
• 3.9. Rare Disease Key Regulations
  • 3.9.1. Rare Disease Key Regulations: North America
  • 3.9.2. Rare Disease Key Regulations: Latin America
  • 3.9.3. Rare Disease Key Regulations: Europe
  • 3.9.4. Rare Disease Key Regulations: Asia Pacific
  • 3.9.5. Rare Disease Key Regulations: Middle East & Africa
• 3.10. Forecast Scenario
• 3.11. PEST Analysis
• 3.12. Porter's Five Forces Analysis
• 3.13. Market Positioning and Behavioral Assessment
• 3.14. Investment Feasibility Assessment
• 3.15. Competitor Market Footprint Matrix
• 3.16. Key Participants Market Presence (Intensity Map) By Region

4. Global Rare Endocrine Disease Treatment Market Analysis and Forecast 2024 - 2031

• 4.1. Global Rare Endocrine Disease Treatment Market Size and Forecast By Indication, 2024 - 2031
  • 4.1.1. Acromegaly Market Size and Forecast, 2024 - 2031
    • 4.1.1.1. Revenue (US$ Mn) Comparison, By Region
    • 4.1.1.2. Market Share Comparison, By Region
    • 4.1.1.3. Y-o-Y growth Comparison, By Region
  • 4.1.2. Central Diabetes Insipidus Market Size and Forecast, 2024 - 2031
    • 4.1.2.1. Revenue (US$ Mn) Comparison, By Region
    • 4.1.2.2. Market Share Comparison, By Region
    • 4.1.2.3. Y-o-Y growth Comparison, By Region
  • 4.1.3. Ahumada-Del Castillo Syndrome Market Size and Forecast, 2024 - 2031
    • 4.1.3.1. Revenue (US$ Mn) Comparison, By Region
    • 4.1.3.2. Market Share Comparison, By Region
    • 4.1.3.3. Y-o-Y growth Comparison, By Region
  • 4.1.4. Hypoparathyroidism Market Size and Forecast, 2024 - 2031
    • 4.1.4.1. Revenue (US$ Mn) Comparison, By Region
    • 4.1.4.2. Market Share Comparison, By Region
    • 4.1.4.3. Y-o-Y growth Comparison, By Region
  • 4.1.5. Other Indications Market Size and Forecast, 2024 - 2031
    • 4.1.5.1. Revenue (US$ Mn) Comparison, By Region
    • 4.1.5.2. Market Share Comparison, By Region
    • 4.1.5.3. Y-o-Y growth Comparison, By Region
• 4.2. Global Rare Endocrine Disease Treatment Market Size and Forecast By Drug Type, 2024 - 2031
  • 4.2.1. Biologics Market Size and Forecast, 2024 - 2031
    • 4.2.1.1. Revenue (US$ Mn) Comparison, By Region
    • 4.2.1.2. Market Share Comparison, By Region
    • 4.2.1.3. Y-o-Y growth Comparison, By Region
  • 4.2.2. Organic Compounds Market Size and Forecast, 2024 - 2031
    • 4.2.2.1. Revenue (US$ Mn) Comparison, By Region
    • 4.2.2.2. Market Share Comparison, By Region
    • 4.2.2.3. Y-o-Y growth Comparison, By Region
• 4.3. Global Rare Endocrine Disease Treatment Market Size and Forecast By Mode of Administration, 2024 - 2031
  • 4.3.1. Injectables Market Size and Forecast, 2024 - 2031
    • 4.3.1.1. Revenue (US$ Mn) Comparison, By Region
    • 4.3.1.2. Market Share Comparison, By Region
    • 4.3.1.3. Y-o-Y growth Comparison, By Region
  • 4.3.2. Oral Market Size and Forecast, 2024 - 2031
    • 4.3.2.1. Revenue (US$ Mn) Comparison, By Region
    • 4.3.2.2. Market Share Comparison, By Region
    • 4.3.2.3. Y-o-Y growth Comparison, By Region
  • 4.3.3. Others Market Size and Forecast, 2024 - 2031
    • 4.3.3.1. Revenue (US$ Mn) Comparison, By Region
    • 4.3.3.2. Market Share Comparison, By Region
    • 4.3.3.3. Y-o-Y growth Comparison, By Region
• 4.4. Global Rare Endocrine Disease Treatment Market Size and Forecast By Distribution Channel, 2024 - 2031
  • 4.4.1. Hospital Pharmacies Market Size and Forecast, 2024 - 2031
    • 4.4.1.1. Revenue (US$ Mn) Comparison, By Region
    • 4.4.1.2. Market Share Comparison, By Region
    • 4.4.1.3. Y-o-Y growth Comparison, By Region
  • 4.4.2. Retail Pharmacies Market Size and Forecast, 2024 - 2031
    • 4.4.2.1. Revenue (US$ Mn) Comparison, By Region
    • 4.4.2.2. Market Share Comparison, By Region
    • 4.4.2.3. Y-o-Y growth Comparison, By Region
  • 4.4.3. Online Pharmacies Market Size and Forecast, 2024 - 2031
    • 4.4.3.1. Revenue (US$ Mn) Comparison, By Region
    • 4.4.3.2. Market Share Comparison, By Region
    • 4.4.3.3. Y-o-Y growth Comparison, By Region

5. North America Rare Endocrine Disease Treatment Market Size and Forecast, 2024 - 2031

• 5.1. North America Outlook
• 5.2. North America Parent Market Outlook
• 5.3. North America Target Market Outlook
• 5.4. Revenue (US$ Mn) Comparison, By Country
  • 5.4.1. US Market Size and Forecast (US$ Mn), 2024 - 2031
  • 5.4.2. Canada Market Size and Forecast (US$ Mn), 2024 - 2031
• 5.5. Revenue (US$ Mn) Comparison, By Indication
• 5.6. Revenue (US$ Mn) Comparison, By Drug Type
• 5.7. Revenue (US$ Mn) Comparison, By Mode of Administration
• 5.8. Revenue (US$ Mn) Comparison, By Distribution Channel

6. Latin America Rare Endocrine Disease Treatment Market Size and Forecast, 2024 - 2031

• 6.1. Latin America Outlook
• 6.2. Latin America Parent Market Outlook
• 6.3. Latin America Target Market Outlook
• 6.4. Revenue (US$ Mn) Comparison, By Country
  • 6.4.1. Brazil Market Size and Forecast (US$ Mn), 2024 - 2031
  • 6.4.2. Mexico Market Size and Forecast (US$ Mn), 2024 - 2031
  • 6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2024 - 2031
• 6.5. Revenue (US$ Mn) Comparison, By Indication
• 6.6. Revenue (US$ Mn) Comparison, By Drug Type
• 6.7. Revenue (US$ Mn) Comparison, By Mode of Administration
• 6.8. Revenue (US$ Mn) Comparison, By Distribution Channel

7. Europe Rare Endocrine Disease Treatment Market Size and Forecast, 2024 - 2031

• 7.1. Europe Outlook
• 7.2. Europe Parent Market Outlook
• 7.3. Europe Target Market Outlook
• 7.4. Revenue (US$ Mn) Comparison, By Country
  • 7.4.1. Germany Market Size and Forecast (US$ Mn), 2024 - 2031
  • 7.4.2. UK Market Size and Forecast (US$ Mn), 2024 - 2031
  • 7.4.3. France Market Size and Forecast (US$ Mn), 2024 - 2031
  • 7.4.4. Spain Market Size and Forecast (US$ Mn), 2024 - 2031
  • 7.4.5. Italy Market Size and Forecast (US$ Mn), 2024 - 2031
  • 7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2024 - 2031
• 7.5. Revenue (US$ Mn) Comparison, By Indication
• 7.6. Revenue (US$ Mn) Comparison, By Drug Type
• 7.7. Revenue (US$ Mn) Comparison, By Mode of Administration
• 7.8. Revenue (US$ Mn) Comparison, By Distribution Channel

8. Japan Rare Endocrine Disease Treatment Market Size and Forecast, 2024 - 2031

• 8.1. Japan Outlook
• 8.2. Japan Parent Market Outlook
• 8.3. Japan Target Market Outlook
• 8.4. Japan Market Size and Forecast (US$ Mn), 2024 - 2031
• 8.5. Revenue (US$ Mn) Comparison, By Indication
• 8.6. Revenue (US$ Mn) Comparison, By Drug Type
• 8.7. Revenue (US$ Mn) Comparison, By Mode of Administration
• 8.8. Revenue (US$ Mn) Comparison, By Distribution Channel

9. APEJ Rare Endocrine Disease Treatment Market Size and Forecast, 2024 - 2031

• 9.1. APEJ Outlook
• 9.2. APEJ Parent Market Outlook
• 9.3. APEJ Target Market Outlook
• 9.4. Revenue (US$ Mn) Comparison, By Country
  • 9.4.1. China Market Size and Forecast (US$ Mn), 2024 - 2031
  • 9.4.2. India Market Size and Forecast (US$ Mn), 2024 - 2031
  • 9.4.3. Thailand Market Size and Forecast (US$ Mn), 2024 - 2031
  • 9.4.4. Singapore Market Size and Forecast (US$ Mn), 2024 - 2031
  • 9.4.5. Australia Market Size and Forecast (US$ Mn), 2024 - 2031
  • 9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2024 - 2031
• 9.5. Revenue (US$ Mn) Comparison, By Indication
• 9.6. Revenue (US$ Mn) Comparison, By Drug Type
• 9.7. Revenue (US$ Mn) Comparison, By Mode of Administration
• 9.8. Revenue (US$ Mn) Comparison, By Distribution Channel

10. MEA Rare Endocrine Disease Treatment Market Size and Forecast, 2024 - 2031

• 10.1. MEA Outlook
• 10.2. MEA Parent Market Outlook
• 10.3. MEA Target Market Outlook
• 10.4. Revenue (US$ Mn) Comparison, By Country
  • 10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2024 - 2031
  • 10.4.2. South Africa Market Size and Forecast (US$ Mn), 2024 - 2031
  • 10.4.3. Nigeria Market Size and Forecast (US$ Mn), 2024 - 2031
  • 10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2024 - 2031
• 10.5. Revenue (US$ Mn) Comparison, By Indication
• 10.6. Revenue (US$ Mn) Comparison, By Drug Type
• 10.7. Revenue (US$ Mn) Comparison, By Mode of Administration
• 10.8. Revenue (US$ Mn) Comparison, By Distribution Channel

11. Global Rare Endocrine Disease Treatment Market Company Share, Competition Landscape and Company Profiles

• 11.1. Company Share Analysis
• 11.2. Competition Landscape
• 11.3. Company Profiles
  • 11.3.1. Novartis
  • 11.3.2. Ipsen
  • 11.3.3. Pfizer, Inc.
  • 11.3.4. Teva
  • 11.3.5. EMD serono
  • 11.3.6. Novo Nordisk
  • 11.3.7. Eli Lilly
  • 11.3.8. Shire
  • 11.3.9. Amgen, Inc.
  • 11.3.10. Corcept Therapeutics
  • 11.3.11. Novelion Therapeutics

12. Key Takeaways

13. Research Methodology

14. Disclaimer